Reviewing Mallinckrodt (OTCMKTS:MNKKQ) & Tyra Biosciences (NASDAQ:TYRA)

Tyra Biosciences (NASDAQ:TYRA) and Mallinckrodt (OTCMKTS:MNKKQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Earnings and Valuation

This table compares Tyra Biosciences and Mallinckrodt”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$69.13 million	($1.51)	-7.19
Mallinckrodt	$1.91 billion	0.00	-$911.20 million	N/A	N/A

Tyra Biosciences has higher earnings, but lower revenue than Mallinckrodt.

Institutional & Insider Ownership

84.1% of Tyra Biosciences shares are owned by institutional investors. 15.4% of Tyra Biosciences shares are owned by insiders. Comparatively, 3.6% of Mallinckrodt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Tyra Biosciences and Mallinckrodt’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-24.56%	-23.31%
Mallinckrodt	-56.33%	-59.80%	-16.98%

Analyst Recommendations

This is a breakdown of current recommendations for Tyra Biosciences and Mallinckrodt, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	0	0	6	0	3.00
Mallinckrodt	0	0	0	0	0.00

Tyra Biosciences currently has a consensus price target of $30.83, suggesting a potential upside of 183.92%. Given Tyra Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Mallinckrodt.

Summary

Tyra Biosciences beats Mallinckrodt on 8 of the 10 factors compared between the two stocks.

About Tyra Biosciences

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

About Mallinckrodt

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.